Linagliptin decreased the tumor progression on glioblastoma model

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Dipeptidyl peptidase-4 (DPP-4) inhibitors are used for type II diabetes.
• DPP-4 is expressed in various tumors and DPP-4 inhibitors have shown tumor suppression in preclinical models.
• Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.

Purpose of the Study:

• To investigate the role of DPP-4 in glioblastoma.
• To evaluate the antitumor effects of the DPP-4 inhibitor linagliptin on GBM.
• To explore the molecular mechanisms underlying linagliptin's action in GBM.

Main Methods:

• Analysis of DPP-4 expression in human GBM tissues and a murine GBM model.
• Assessment of linagliptin's effects on GBM cell viability, proliferation, and migration in vitro.
• Evaluation of linagliptin's impact on protein expression, including phosphorylated NF-kB, cell cycle, and cell adhesion markers.
• Testing the antitumor efficacy of linagliptin in a murine GBM model.

Main Results:

• DPP-4 expression was upregulated in human GBM and correlated with glioma grade.
• Linagliptin significantly suppressed GBM cell viability, proliferation, and migration.
• Linagliptin treatment altered the expression of proteins involved in cell cycle and cell adhesion, including phosphorylated NF-kB.
• Oral administration of linagliptin reduced tumor progression in the murine GBM model.

Conclusions:

• DPP-4 inhibition by linagliptin demonstrates significant antitumor activity against GBM in vitro and in vivo.
• The observed antitumor effects are likely mediated by the modulation of phosphorylated NF-kB, cell cycle, and cell adhesion pathways.
• DPP-4 inhibitors, such as linagliptin, represent a potential novel therapeutic strategy for GBM treatment.